Pericoital UPA + Meloxicam

Description: Dosing of ulipristal acetate and meloxicam given at a peak fertility time point. Ulipristal is effective during the follicular time period and the theoretical mechanism of meloxicam to disruption of cumulus-oocyte expansion in a late step of ovulation.

Product Details

User: Female

Hormonal: Yes

Delivery Method: Oral

Duration Type: Pericoital

Regimen:
  • single

Dose: ulipristal acetate 30mg plus meloxicam 15mg

Active Pharmaceutical Ingredient (API):
  • ulipristal acetate
  • meloxicam

Multipurpose Preventive Technology (MPT): No

Status Details

Developer: Stanford University

Project Phase: Pre-Clinical and Clinical Development

Development Stage: Phase I

Began discovery in: 2017

Active Development: Yes

Status Details:
  • Exploratory prospective study initiated in January 2018 investigating if addition of a COX-2 inhibitor can increase efficacy of ulipristal in disrupting ovulation at peak fertility. Expected study completion in July 2018.

Additional Information

References:
  • ClinicalTrials.gov Identifier: NCT03354117

Vertical Tabs

Print